An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Inclusion Criteria: * Mild to moderate AD per NIA-AA. * History of cognitive and functional decline over at least 1 year. * MMSE scores between 11 and 24 (inclusive) at baseline. * Hachinski Ischemic Score (HIS) scale total score ≤ 4. * Hamilton Rating Scale for Depression/17 items (HAMD) total score ≤ 10. * Brain MRI scan show the highest possibility of AD. * Have a reliable study partner/caregiver. * Sign the informed consent form. Exclusion Criteria: * Diagnosis of a dementia-related central nervous system disease other than AD. * Major structural brain disease as judged by MRI. * A resting heart rate of \< 50 beats per minute (bpm) after 10 minutes of rest. * Major medical illness or unstable medical condition within 12 months of screening. * Concomitant use of donepezil, rivastigmine, galanthamine, huperzine A, memantine, or aducanumab within 6 moinths prior to baseline. * Inadequate hepatic function. * Inadequate organ function. * ECG clinically significant abnormalities.